2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer
Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer. Cancer 2015, 121: 4165-4172. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerProgressive brain metastasesBrain metastasesCell lung cancerAdverse eventsStudy drugLung cancerGrade 3/4 adverse eventsMulticenter phase 2 studyNSCLC brain metastasesSteady-state distribution volumePhase 1/2 studyRecurrent brain metastasesPhase 2 studyProgression-free survivalFirst prospective studyConcentration-time curvePrimary endpointAdult patientsOverall survivalPulmonary embolismMedian agePeripheral neuropathyMedian timeProspective study
2010
Neurological Complications of Non-Hodgkin Lymphoma
Khasraw M, Noy A, Gilbert M, Omuro A. Neurological Complications of Non-Hodgkin Lymphoma. 2010, 267-285. DOI: 10.1007/978-1-4419-7668-0_16.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaPeripheral nervous systemBrain metastasesCNS involvementCNS prophylaxisDirect complicationsNeurological complicationsParaneoplastic disordersPeripheral neuropathyLeptomeningeal metastasesNeurological symptomsHodgkin's lymphomaRisk factorsNervous systemComplicationsNHLLymphomaMetastasisInvolvementMyelopathyPlexopathyProphylaxisNeuropathyDirect involvementSymptoms